Assess whether to resubmit, meet, or pause the program (6b8b6a)

SITUATION A boxed-warning proposal from the review division put 505(b)(2) literature-to-product bridge table in front of regulatory-affairs lead in a rare-disease team designing a pediatric plan. This Pharma & Life Sciences / Pharmacovigilance close is to resubmit, meet, or from 505(b)(2) literature-to-product bridge table, and the live options are To resubmit, meet,, Pause the program.

DECISION Regulatory-affairs lead in a rare-disease team designing a pediatric plan must choose To resubmit, meet, / Pause the program using 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; 505(b)(2) literature-to-product bridge table already has the discriminator after a boxed-warning proposal from the review division. 2. Keep Pause the program in force until 505(b)(2) literature-to-product bridge table is completed after a boxed-warning proposal from the review division for regulatory-affairs lead. 3. Treat 505(b)(2) literature-to-product bridge table as To resubmit, meet, because both readings appear after a boxed-warning proposal from the review division. 4. Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the decision to resubmit, meet, or turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a boxed-warning proposal from the review division and write the one fact that would move to resubmit, meet, or for regulatory-affairs lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division). The follow-on Pharmacovigilance action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for regulatory-affairs lead - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in 505(b)(2) literature-to-product bridge table that a second reviewer can re-perform